Bionas cell profiling device selected by Solvay Pharmaceuticals for Target Validation

Print
Wednesday, 08 November 2006 00:00 (UTC + 1)

 

Bionas GmbH (Rostock, Germany) and Solvay Pharmaceuticals Research Laboratories (Weesp, The Netherlands) announce that the Bionas(r) 2500 analyzing system has been recognized to be a valuable tool for target validation studies.

 

"It is known that angiotensin 1-8 (angiotensin II) acts via two receptors. The AT1 receptor mediates vasoconstriction upon stimulation, whereas the AT2 receptor is implicated in hypotensive effects. However, the mechanism through which angiotensin 1-7 induces its powerful hypotensive effect were unclear," explains Dr. Eric Ronken, Principal Scientist at Solvay.

 

On-line monitoring of endothelial cell physiology and its changes upon challenges by angiotensin 1-7 helped in delineating the mechanism of action by this peptide. The Bionas(r) 2500 analyzing system is well suited for such experiments, as it measures cellular acidification, oxygen consumption and cell adhesion simultaneously in a label-free and non-invasive way. "The Bionas system allows us to extend and optimize target validation studies by bringing the targets back into their physiological context", says Dr. Eric Ronken.

 

The Bionas 2500 analyzing system gives a complete overview over the physiologic state of cells. It can be used to discriminate between different signal transduction pathways allowing target validation studies at an early stage in the drug discovery process. Recently, Bionas announced the usefulness of its device to predict liver toxicity in primary human hepatocytes and standardized HepG2 cells.


About Bionas - www.bionas.de
Bionas GmbH, situated in Rostock, Germany, specializes in analyzing systems and services for in-vitro profiling the metabolic activity of cells to understand cellular function. Bionas(r) 2500 analyzing system measures extracellular acidification, oxygen consumption and cell adhesion in a label-free and non-invasive way and can be applied to various cell types including primary cells. The readout is carried out continuously and can be watched online. Main applications include drug profiling, lead optimization, pharmaco kinetics, early toxicology programs, ADME/Tox, chemosensitivity testing, toxicological testing of chemical substances (REACH) and cell culture monitoring/optimization. Micronas Holding GmbH and GENIUS Venture Capital GmbH fund the company.

 

About Solvay - www.solvay.com
SOLVAY is an international chemical and pharmaceutical Group with headquarters in Brussels. It employs some 30,000 people in 50 countries.  In 2005 its consolidated sales amounted to EUR 8.6 billion generated by its three activity sectors: Chemicals, Plastics and Pharmaceuticals. SOLVAY (Euronext : SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLBt.BR) is listed on the Euronext stock exchange in Brussels.


Contact at Bionas GmbH:
Dr. Michael Schulze
Bionas GmbH
Tel.: +49 381 5196-241
email:  This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 

Contact at Solvay Pharmaceuticals:
Dr. Eric Ronken
Solvay Pharmaceuticals Research Laboratories
Phone +31(0)294 479853
e-mail This e-mail address is being protected from spambots. You need JavaScript enabled to view it